New vaccine combo shows promise in shrinking Hard-to-Treat tumors
NCT ID NCT06631079
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This study tests a personalized cancer vaccine (NECVAX-NEO1) given alongside standard immunotherapy drugs (PD-1/PD-L1 inhibitors) in 20 adults with solid tumors. The goal is to see if the combination is safe and helps control the disease better than immunotherapy alone. Participants must have stable or partially responding tumors after starting immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHUS Santiago de Compostela
Santiago de Compostela, Spain
-
Charité
Berlin, Germany
-
Comprehensive Cancer Center
Munich, Germany
-
Fundacion Jimenez Diaz
Madrid, Spain
-
Institut Catala d'Oncologia
Barcelona, Spain
-
NCT
Heidelberg, Germany
-
National Cancer Center
Vilnius, Lithuania
-
Vall d'Hebron
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.